Wenbin Jiang's most recent trade in Cytek BioSciences Inc was a trade of 57,212 Restricted Stock Units done . Disclosure was reported to the exchange on Aug. 18, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2026 | 57,212 | 820,054 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2026 | 57,212 | 5,581,985 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2026 | 29,002 | 299,694 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2026 | 29,002 | 5,531,835 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2026 | 22,100 | 5,508,215 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2026 | 22,100 | 139,973 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.67 per share. | 18 Aug 2026 | 20,956 | 5,561,029 | - | 4.7 | 97,865 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2026 | 11,781 | 27,494 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2026 | 11,781 | 5,488,984 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.67 per share. | 18 Aug 2026 | 7,062 | 5,524,773 | - | 4.7 | 32,980 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.67 per share. | 18 Aug 2026 | 5,382 | 5,502,833 | - | 4.7 | 25,134 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.67 per share. | 18 Aug 2026 | 2,869 | 5,486,115 | - | 4.7 | 13,398 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 May 2026 | 38,141 | 877,266 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 38,141 | 5,492,212 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 May 2026 | 19,334 | 328,696 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 19,334 | 5,459,103 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 15,009 | 5,477,203 | - | 3.6 | 53,282 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 14,733 | 5,443,357 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 May 2026 | 14,733 | 162,073 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2026 | 7,854 | 5,430,537 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 May 2026 | 7,854 | 39,275 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 5,032 | 5,454,071 | - | 3.6 | 17,864 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 3,588 | 5,439,769 | - | 3.5 | 12,737 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.55 per share. | 18 May 2026 | 1,913 | 5,428,624 | - | 3.5 | 6,791 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2026 | 915,407 | 915,407 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2026 | 485,545 | 485,545 | - | - | Employee Stock Option (right to buy) | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2026 | 38,669 | 348,030 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 38,669 | 5,432,099 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 38,669 | 5,432,099 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 38,669 | 5,432,099 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2026 | 29,467 | 176,806 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 29,467 | 5,401,177 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 29,467 | 5,401,177 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 29,467 | 5,401,177 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2026 | 15,708 | 47,129 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 15,708 | 5,375,535 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 15,708 | 5,375,535 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 15,708 | 5,375,535 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 9,416 | 5,422,683 | - | 4.2 | 39,830 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 9,416 | 5,422,683 | - | 4.2 | 39,830 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 9,416 | 5,422,683 | - | 4.2 | 39,830 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 7,747 | 5,393,430 | - | 4.2 | 32,770 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 7,747 | 5,393,430 | - | 4.2 | 32,770 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 7,747 | 5,393,430 | - | 4.2 | 32,770 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 3,825 | 5,371,710 | - | 4.2 | 16,180 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 3,825 | 5,371,710 | - | 4.2 | 16,180 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.23 per share. | 10 Mar 2026 | 3,825 | 5,371,710 | - | 4.2 | 16,180 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 4,514 | 5,361,166 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Feb 2026 | 4,514 | 0 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 4,514 | 5,361,166 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2026 | 4,514 | 5,361,166 | - | - | - | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.20 per share. | 18 Feb 2026 | 1,339 | 5,359,827 | - | 4.2 | 5,624 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.20 per share. | 18 Feb 2026 | 1,339 | 5,359,827 | - | 4.2 | 5,624 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.20 per share. | 18 Feb 2026 | 1,339 | 5,359,827 | - | 4.2 | 5,624 | - |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 29,002 | 5,368,065 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Nov 2025 | 29,002 | 386,699 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 22,100 | 5,347,760 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Nov 2025 | 22,100 | 206,273 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 11,781 | 5,330,296 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Nov 2025 | 11,781 | 62,837 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 11,413 | 5,356,652 | - | 5.5 | 63,114 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 8,697 | 5,339,063 | - | 5.5 | 48,094 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Nov 2025 | 6,758 | 4,514 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 6,758 | 5,321,175 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 4,636 | 5,325,660 | - | 5.5 | 25,637 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.53 per share. | 18 Nov 2025 | 2,660 | 5,318,515 | - | 5.5 | 14,710 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2025 | 29,002 | 415,701 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 29,002 | 5,321,479 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 22,100 | 5,297,859 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2025 | 22,100 | 228,373 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 11,781 | 5,278,628 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2025 | 11,781 | 74,618 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 7,062 | 5,314,417 | - | 4.1 | 28,672 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 6,758 | 5,268,493 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Aug 2025 | 6,758 | 11,272 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 5,382 | 5,292,477 | - | 4.1 | 21,851 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 2,869 | 5,275,759 | - | 4.1 | 11,648 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 18 Aug 2025 | 1,646 | 5,266,847 | - | 4.1 | 6,683 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 19 May 2025 | 19,334 | 444,703 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 19,334 | 5,266,443 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 19 May 2025 | 14,733 | 250,473 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 14,733 | 5,250,697 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 7,854 | 5,237,877 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 19 May 2025 | 7,854 | 86,399 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2025 | 6,758 | 5,231,669 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 19 May 2025 | 6,758 | 18,030 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 4,708 | 5,261,735 | - | 2.7 | 12,665 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 3,588 | 5,247,109 | - | 2.7 | 9,652 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 1,913 | 5,235,964 | - | 2.7 | 5,146 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.69 per share. | 19 May 2025 | 1,646 | 5,230,023 | - | 2.7 | 4,428 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2025 | 29,467 | 265,206 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 29,467 | 5,232,909 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 15,708 | 5,208,100 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 10 Mar 2025 | 15,708 | 94,253 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 7,998 | 5,224,911 | - | 4.4 | 34,871 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.36 per share. | 10 Mar 2025 | 4,658 | 5,203,442 | - | 4.4 | 20,309 | Common Stock |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 04 Mar 2025 | 735,294 | 735,294 | - | - | Employee Stock Option (right to buy) | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 04 Mar 2025 | 464,037 | 464,037 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 6,758 | 5,194,396 | - | - | Common Stock | |
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | 18 Feb 2025 | 6,758 | 24,788 | - | - | Restricted Stock Units | ||
| Cytek BioSciences Inc | Dr. Wenbin Jiang, PhD | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.31 per share. | 18 Feb 2025 | 2,004 | 5,192,392 | - | 5.3 | 10,641 | Common Stock |